Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM (Q40821842)
Jump to navigation
Jump to search
scientific article published on July 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM |
scientific article published on July 2015 |
Statements
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) (English)
Kristian Reich
Craig L Leonardi
Leon Kircik
Sergio Chimenti
Richard G B Langley
ChiaChi Hu
Randall M Stevens
Kenneth B Gordon